Table 1.
Patient characteristics and treatment strategies of crude and propensity score (PS)-matched cohorts
| Crude | After PS match | |||||||||
| TZ | NT | Total | TZ | NT | Total | |||||
| (N=1005) | (N=11 055) | (N=12 060) | P value | (N=1005) | (N=2010) | (N=3015) | P value | |||
| Age | ||||||||||
| N | 1005 | 11 055 | 12 060 | 1005 | 2010 | 3015 | ||||
| Mean (SD) | 51.1 (8.90) | 50.8 (8.53) | 50.8 (8.56) | 0.2746 | * | 51.1 (8.90) | 51.4 (8.71) | 51.3 (8.77) | 0.3454 | * |
| Median | 51 | 50 | 50 | 51 | 51 | 51 | ||||
| (IQR) | (45.0, 57.0) | (45.0, 56.0) | (45.0, 56.0) | (45.0, 57.0) | (45.0, 57.0) | (45.0, 57.0) | ||||
| Cardiovascular risk factors | ||||||||||
| DM(E10-E14, A10) | 26 (2.6%) | 225 (2.0%) | 251 (2.1%) | 0.2407 | † | 26 (2.6%) | 57 (2.8%) | 83 (2.8%) | 0.6939 | † |
| HT(I10-I15, C03, C07-C09) | 68 (6.8%) | 661 (6.0%) | 729 (6.0%) | 0.3162 | † | 68 (6.8%) | 149 (7.4%) | 217 (7.2%) | 0.5171 | † |
| DL(E78, C10) | 36 (3.6%) | 465 (4.2%) | 501 (4.2%) | 0.3424 | † | 36 (3.6%) | 73 (3.6%) | 109 (3.6%) | 0.945 | † |
| Baseline assessments | ||||||||||
| Ehocardiography(160 072 510) | 286 (28.5%) | 2175 (19.7%) | 2461 (20.4%) | <0.0001 | † | 286 (28.5%) | 464 (23.1%) | 750 (24.9%) | 0.0013 | † |
| MMG(170 026 910) | 911 (90.6%) | 10 364 (93.7%) | 11 275 (93.5%) | 0.0001 | † | 911 (90.6%) | 1899 (94.5%) | 2810 (93.2%) | <0.0001 | † |
| US_Br(160 165 010) | 994 (98.9%) | 10 938 (98.9%) | 11 932 (98.9%) | 0.9147 | † | 994 (98.9%) | 1987 (98.9%) | 2981 (98.9%) | 0.9029 | † |
| CNB(D410) | 727 (72.3%) | 7747 (70.1%) | 8474 (70.3%) | 0.1332 | † | 727 (72.3%) | 1444 (71.8%) | 2171 (72.0%) | 0.7742 | † |
| ER(160 060 350) | 881 (87.7%) | 9445 (85.4%) | 10 326 (85.6%) | 0.0542 | † | 881 (87.7%) | 1737 (86.4%) | 2618 (86.8%) | 0.341 | † |
| HER2(160 173 550) | 863 (85.9%) | 9017 (81.6%) | 9880 (81.9%) | 0.0007 | † | 863 (85.9%) | 1689 (84.0%) | 2552 (84.6%) | 0.1863 | † |
| Treatment strategies | ||||||||||
| Radiotherapy(M000, M001) | 486 (48.4%) | 6019 (54.4%) | 6505 (53.9%) | 0.0002 | † | 486 (48.4%) | 960 (47.8%) | 1446 (48.0%) | 0.7571 | † |
| Systemic therapy(L01, L02) | 1005 (100.0%) | 4822 (43.6%) | 5827 (48.3%) | <0.0001 | † | 1005 (100.0%) | 1449 (72.1%) | 2454 (81.4%) | <0.0001 | † |
| Alkyl(L01A) | 738 (73.4%) | 2385 (21.6%) | 3123 (25.9%) | <0.0001 | † | 738 (73.4%) | 1233 (61.3%) | 1971 (65.4%) | <0.0001 | † |
| Anti Metab(L01B) | 230 (22.9%) | 820 (7.4%) | 1050 (8.7%) | <0.0001 | † | 230 (22.9%) | 455 (22.6%) | 685 (22.7%) | 0.8779 | † |
| Vinca(L01C1) | 6 (0.6%) | 24 (0.2%) | 30 (0.2%) | 0.0206 | † | 6 (0.6%) | 12 (0.6%) | 18 (0.6%) | 1.0000 | † |
| Taxan(L01C2) | 780 (77.6%) | 2109 (19.1%) | 2889 (24.0%) | <0.0001 | † | 780 (77.6%) | 997 (49.6%) | 1777 (58.9%) | <0.0001 | † |
| Anthra(L01D) | 591 (58.8%) | 1594 (14.4%) | 2185 (18.1%) | <0.0001 | † | 591 (58.8%) | 1182 (58.8%) | 1773 (58.8%) | 1.0000 | † |
| Trastuzumab(L01XC03) | 1005 (100.0%) | 0 (0.0%) | 1005 (100.0%) | 0 (0.0%) | ||||||
| Hormone Anti(L02B) | 651 (64.8%) | 8032 (72.7%) | 8683 (72.0%) | <0.0001 | † | 651 (64.8%) | 1310 (65.2%) | 1961 (65.0%) | 0.8289 | † |
| SERM(L02B1) | 388 (38.6%) | 5486 (49.6%) | 5874 (48.7%) | <0.0001 | † | 388 (38.6%) | 841 (41.8%) | 1229 (40.8%) | 0.0885 | † |
| Aroma I(L02B3) | 327 (32.5%) | 3370 (30.5%) | 3697 (30.7%) | 0.1765 | † | 327 (32.5%) | 646 (32.1%) | 973 (32.3%) | 0.8256 | † |
| AntiEmet(A04A) | 831 (82.7%) | 2681 (24.3%) | 3512 (29.1%) | <0.0001 | † | 831 (82.7%) | 1271 (63.2%) | 2102 (69.7%) | <0.0001 | † |
| CSF(L03A1) | 455 (45.3%) | 1359 (12.3%) | 1814 (15.0%) | <0.0001 | † | 455 (45.3%) | 713 (35.5%) | 1168 (38.7%) | <0.0001 | † |
| Trastuzumab use | ||||||||||
| Duration (months) | ||||||||||
| Mean (SD) | 11.7 (2.98) | 11.7 (2.98) | ||||||||
| Median | 13 | 13 | ||||||||
| (IQR) | (12.0, 13.0) | (12.0, 13.0) | ||||||||
| First dose after surgery (months) | ||||||||||
| Median | 4 | 4 | ||||||||
| (IQR) | (2.0, 5.0) | (2.0, 5.0) | ||||||||
*Equal variance two sample t-test.
† Chi-square p value.
Alkyl, alkylating agents (eg, cyclophosphamide [L01AA01]); Anthra, anthracyclines (eg, doxorubicin [L01DB01], epirubicin [L01DB03]); AntiEmet, antiemetics; Anti Metab, antimetabolites (eg, 5-fluorouracil [(L01BC02]), capecitabine [L01BC06]); Aroma_I, aromatase inhibitors (eg, anastrozole [L02BG03], letrozole [L02BG04]); CNB, needle biopsy; CSF, colony-stimulating factors; DL, dyslipidaemia; DM, diabetes mellitus; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; HT, hypertension; MMG, mammography; NT, non-users; SEAM, anti-oestrogens (eg, tamoxifen [L02BA01], toremifene [L02BA02], fulvestrant [L02BA03]); Taxan(s), (eg, paclitaxel [L01CD01], docetaxel [L01CD02]); TZ, trastuzumab users; US_Br, breast ultrasound; Vinca, vinca alkaloids.